Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Dose-escalation Phase I Study to Assess the Safety and PK/PD of LBL-047 Subcutaneous Injection in Healthy Adults and Patients With Systemic Lupus Erythematosus

NCT07323173 is registered in ClinicalTrials.gov with Nanjing Leads Biolabs Co.,Ltd as lead sponsor.

NCT NCT07323173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07323173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Dose-escalation Phase I Study to Assess the Safety and PK/PD of LBL-047 Subcutaneous Injection in Healthy Adults and Patients With Systemic Lupus Erythematosus
Lead sponsor
Nanjing Leads Biolabs Co.,Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
December 16, 2025
Completion date
December 16, 2027
Enrollment
117 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus